Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that infects from 60% to nearly 80% of the human population worldwide and, although rarely, causes serious multi-organ infections, such as pneumonia, gastrointestinal diseases and retinitis, which can be fatal in immunosuppressed patients. Additionally, congenital HCMV is associated with neurodevelopmental defects including hearing loss and mental deficits.
To date, there are no vaccines available to prevent HCMV infections, and no drugs have been approved for the treatment of congenital infections. In addition, the drugs currently in use in adults have low bioavailability, non-negligible toxicity, limited efficacy and are subject to drug resistance.
This invention relates to the novel use of clinically approved antifungal compounds, such as posaconazole and isavuconazole, as antivirals to treat HCMV associated infections.

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Loregian
Arianna

Mercorelli
Beatrice

Gribaudo
Giorgio

Luganini
Anna

Download the brochure

  • Use of small molecules to rescue folding defective proteins

    The use of CFTR (cystic fibrosis transmembrane conductance regulator) correctors for the treatment of rare and devastating genetic muscular diseases, namely sarcoglycanopathies and Brody myopathy, is the object of this invention. Sarcoglycanopathies and Brody myopathy are rare inherited striated muscle[...]

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • Therapeutic use of redox cyclers in diseases linked to mitochondrial respiratory chain dysfunction

    Mitochondrial disorders are debilitating and life-threatening diseases that still lack effective treatment. They are due to genetic defects affecting oxidative phosphorylation, thus mitochondrial fitness and ATP production. Patients with complex III dysfunction develop progressive neurological impairment, myopathy and meet an[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation